Caen Cedex 5

• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) … Recruiting
  2023-504323-25-01 5 2024-03-19 breast cancer
• Treatment for breast cancer patients with meninges invaded by tumor cells Recruiting
  2022-502351-60-00 4 2024-02-22 Patients having a HER2-amplified metastatic breast cancer with evoluti
• Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib … Recruiting
  2023-503708-10-00 5 2024-02-20 Locally advanced or metastatic breast cancer
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Tucatinib in combination with Oral Etoposide (VP16) and Trastuzumab in Patients with metastatic HER2+ Breast cancer (TUC-TOC) Recruiting
  2022-500743-20-00 4 2023-12-19 Metastatic HER2+ Breast cancer
• Study aiming to assess the clinical impact of dostarlimab on occurrence of second primary cancer in patients with cured primary cancer Recruiting
  2022-501316-34-00 4 2023-11-27 Patient cured from a primary cancer and at risk of 2nd cancer
• Capsaicin 179 mg patch versus oral Duloxetine in patients with chemotherapy-induced peripheral neuropathy: a phase 3 randomized multicentric … Recruiting
  2023-504618-31-00 5 2023-10-20 Chemotherapy induced peripheral neuropathy (CIPN)
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting
  2022-501904-83-00 7 2023-09-11 Ovarian Cancer
• A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting
  2023-504263-16-00 5 2023-05-25 This is an extension study designed to provide continued treatment for
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran … Recruiting
  2024-512878-98-00 9 2023-05-16 Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breas
• EDEN : Etude de désescalade thérapeutique et d'évaluation du marqueur miRNA M371 pour les séminomes de stade IIa/IIb < 3 cm Recruiting
  2024-514636-25-00 4 2023-05-04 Stage IIa/IIb < 3 cm seminoma
• A study investigating the use of EP0031 in patients with cancers having an abnormal RET gene. Recruiting
  2022-501636-42-00 9 2023-03-21 Advanced RET-altered malignancies
• A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting
  2023-505065-91-00 4 2023-01-30 Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
• TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting
  2024-517414-15-00 4 2023-01-25 ER positive HER2 negative breast cancer
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma Recruiting
  2024-510653-10-00 5 2021-06-04 Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years
• CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokin … Recruiting
  2024-518362-27-00 1 2021-05-18 Patients with recurrent and/or metastatic solid cancer.
• Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small … Recruiting
  2023-505924-71-00 4 2021-05-12 Adult patients with metastatic and/or unresectable Non-Small Cell Lung
• AGADIR : Atezolizumab combined with EIK10001 (BDB001) and Immunogenic Radiotherapy in Patients with Advanced Solid Tumors Recruiting
  2023-509492-16-00 4 2021-03-30 Adult participants with metastatic (advanced) solid tumors.
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer

Showing 121–144 of 283 trials